Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592539 | 0.84 | MAPT (0.58) | GAAEPHX1RAB9AMAPTALDH1A1 | |
| SCHEMBL28786813 | 0.83 | MAPT (0.65) | GAAEPHX1RAB9AMAPTALDH1A1 | |
| SCHEMBL9424755 | 0.82 | EPHX1 (0.46) | GAAEPHX1RAB9AMAPTALDH1A1 | |
| SCHEMBL28703728 | 0.81 | ADRB1 (0.49) | GAAEPHX1ALDH1A1KDM4EHPGD | |
| SCHEMBL3613703 | 0.81 | NPC1 (0.56) | GAARAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14385666 | 0.80 | EPHX1 (0.69) | GAAEPHX1RAB9AMAPTALDH1A1 | |
| Bicarbonate SCHEMBL3549893 | 0.79 | MAPT (0.60) | GAAEPHX1RAB9AMAPTALDH1A1 | |
| SCHEMBL12100948 | 0.79 | GAA (0.56) | GAAEPHX1RAB9AMAPTALDH1A1 | |
| SCHEMBL5523949 | 0.79 | MAPT (0.58) | GAARAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5003684 | 0.78 | MAPT (0.72) | GAAEPHX1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249702-B | N-aryl- [2,4 '-dithiazole ] -2' -amine compound and preparation and application thereof | 沈阳药科大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-114249702-A | N-aryl- [2,4 '-bithiazole ] -2' -amine compound and preparation and application thereof | 沈阳药科大学 | 2022-03-29 | — | — | CN | disclosed |
| EP-2718290-B1 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | CLEVEXEL PHARMA (FR) | 2016-05-04 | — | — | EP | disclosed |
| EP-2718290-B1 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | CLEVEXEL PHARMA (FR) | 2016-05-04 | — | — | EP | disclosed |
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| US-20120316148-A1 | Compositions and Methods for Modulating a Kinase | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-12-13 | — | — | US | disclosed |
| EP-1467981-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | Kylix Pharmaceuticals B.V. (NL) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062215-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | KYLIX PHARMACEUTICALS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316148-A1 | Compositions and Methods for Modulating a Kinase | PRKCH, MAP3K2, MAP3K6 | GAA 3797/4885EPHX1 3163/4885RAB9A 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.